Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial

Documenti analoghi

• Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry
  di: Philip Mease, et al.
  Pubblicazione: (2024)
• Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
  di: Stefan Siebert, et al.
  Pubblicazione: (2024)
• Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
  di: Joseph F. Merola, et al.
  Pubblicazione: (2026)
• Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)
• Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients With and Without a Family History of Psoriatic Disease
  di: Catherine Howe, et al.
  Pubblicazione: (2025)